YOLFTbeta
SoftOx Solutions AS

SoftOx Solutions AS

SOFTX · OL · Healthcare / Biotechnology

0.1016NOK+0.00 (+0.40%)

Price History

Full chart

Market Stats

Previous Close0.1012
Open0.1012
Day Range0.0985 – 0.103
52-Week Range0.049 – 0.1658
Volume5.61M
Market Cap345.26M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta0.96
50-Day Avg0.1026
200-Day Avg0.0932

About

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thomas Bjarnsholt
  • Employees2
  • HeadquartersFridtjof Nansens vei 16, Lysaker, Norway, 1364, Norway
  • Websitehttps://soft-ox.com

Leadership

  • Mr. Ulrik SporkExecutive Chairman of the Board
  • Mr. Thomas BjarnsholtCEO, Chief Medical Officer & Chief Scientific Officer
  • Ms. Ingrid JuvenCOO & CFO
  • Ms. Charlotte PinholtHead of CMC
  • Ms. Elin Lisby Kastberg JørgensenInternational Senior Project Manager

Financials

Income Statement

Currency: NOK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue101.00K1.00K4.32M4.10M9.84M7.90M7.11M6.98M7.91M0
Growth (%)--99.01%+432214.00%-5.18%+140.04%-19.70%-9.97%-1.88%+13.38%-100.00%
Operating Income-9.01M-13.17M-17.29M-21.87M-51.36M-86.10M-91.05M-32.63M-32.46M-11.37M
Operating Margin-8919.47%-1316858.00%-399.86%-533.55%-522.03%-1089.75%-1280.01%-467.55%-410.20%-
EBITDA---20.49M-20.33M-48.66M-82.32M-87.56M-25.67M-35.92M-8.18M
EBITDA Margin---474.06%-495.98%-494.56%-1041.88%-1230.92%-367.78%-453.84%-
Net Income-6.22M-9.41M-12.93M-16.34M-37.41M-86.29M-71.14M-39.45M-42.94M-10.81M
Net Income Margin-6153.87%-940827.00%-299.06%-398.54%-380.17%-1092.14%-1000.07%-565.17%-542.64%-
Interest Expense00502146.37K087.81K2.24M8.93M9.17M-
Interest Expense % of Total Revenue0.00%0.00%0.01%3.57%0.00%1.11%31.46%127.99%115.88%-

Balance Sheet

Currency: NOK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.86M31.04M23.39M104.96M87.31M107.18M77.83M97.24M121.14M33.93M
Total Liabilities6.38M4.19M8.98M18.50M11.09M18.33M61.83M94.87M25.96M10.98M
Total Equity2.48M26.85M14.41M86.47M76.22M88.85M16.01M2.37M95.18M22.95M
Cash301.99K17.10M1.24M76.00M34.80M56.98M6.91M7.65M10.51M19.79M
Net Debt--763.47K---42.98M66.35M--

Cash Flow

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.34M-14.94M-10.56M-60.39M-72.56M-85.94M756.68K32.56M-18.87M
Investing Cash Flow-1.49M-1.44M-3.20M-7.67M-4.60M-4.85M-7.61M-19.83M-
Financing Cash Flow33.62M521.59K88.52M26.86M99.34M40.72M7.60M-9.86M-
Capital Expenditure1.49M1.44M3.20M7.67M4.60M4.85M7.61M19.83M0
Free Cash Flow--14.94M-13.76M-68.06M-72.56M-90.79M-6.85M12.73M-18.87M
FCF to OCF-100.00%130.31%112.70%100.00%105.65%-905.61%39.08%100.00%

Earnings

Report DateJun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 31, 2021Jun 30, 2021Nov 17, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 27, 2024Jun 20, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate------------------------------
EPS Actual-0.34-0.15-0.12-0.24-0.29-0.10-0.17-0.24-0.32-0.40-0.63-0.60-2.40-0.60-0.51-0.59-0.07-0.06-0.13-0.14-1.29-0.97-0.01-0.01-0.000.00-0.00-0.00-0.00-0.00
Surprise------------------------------
Timing--------------------Pre-marketPre-market--------

Key Statistics & Ratios

Market Cap345.26M
Enterprise Value303.77M
Trailing P/E0.00
Forward P/E0.00
Price / Sales24.87
Price / Book13.65
EPS0.00
Book Value0.01
Revenue (TTM)13.88M
Gross Profit (TTM)13.88M
EBITDA-19.60M
Profit Margin-165.83%
Operating Margin-447.27%
Return on Equity-34.39%
Return on Assets-18.86%
Shares Outstanding2.66B
Shares Float1.64B
Beta0.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 2, 201850:1